[The relationship between drug sensitivity and expression of drug resistance gene mutations in non-small cell lung cancer].
To study the relationship between the expression of drug resistance genes and the results of drug sensitivity test. Surgical or biopsy specimens from 48 patients with non-small cell lung cancer (NSCLC) were measured for drug sensitivity by Annexin V combined with PI using flow cytometry. The drug resistance genes MDR(1), GST-pi and MPR were measured by RT-PCR. The relationship between expression of drug resistance gene mutations and the drug sensitivity of lung cancer was analyzed. The anti-tumor cytotoxicity of MMC, DDP, VDS, NVB, TAX, GEM, VP-16 and VCR were measured, and their respective tumor inhibition rates were (10.3 +/- 17.1)%, (20.7 +/- 22.2)%, (5.6 +/- 14.9)%, (7.9 +/- 16.2)%, (15.7 +/- 21.8)%, (11.2 +/- 13.8)%, (9.7 +/- 20.1)%, and (4.7 +/- 8.7)%. The positive rates of MDR(1), MRP and GST-pi expression were 67% (32/48), 42% (20/48), and 48% (23/48) respectively. There was no association between the expression of drug resistance genes MRP and GST-pi and the pathology or the stage of lung cancer. Interestingly, the over-expression of MRP was related to drug resistance to NVB, VDS and MMC; while the over-expression of GST-pi was related to resistance to DDP. No relationship was found between MDR(1) over-expression and drug resistance. The expression of some drug resistance genes is related to drug sensitivity test. The detection of the genes may be clinically useful in the administration of chemotherapy.